Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

Infliximab-induced acute hepatitis during Crohn's disease therapy: Absence of cross-toxicity with adalimumab

(2010) A. Haennig et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Viral hepatitis and inflammatory bowel disease

(2010) Jason K. Hou et al.   INFLAMMATORY BOWEL DISEASES

Infliximab-related hepatitis: discussion of a case and review of the literature

(2010) Stefano Mancini et al.   Internal and Emergency Medicine

Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: Preliminary data

(2010) Andrea Paradisi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficiency and Safety of Etanercept after Acute Hepatitis Induced by Infliximab for Psoriasis

(2009) N Kluger et al.   ACTA DERMATO-VENEREOLOGICA

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection

(2009) S. E. Behnam et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

(2009) Sophia Li et al.   CLINICAL RHEUMATOLOGY

Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

(2009) K. M. Carlsen et al.   CLINICAL RHEUMATOLOGY

Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report

(2009) F. Prignano et al.   Dermatologic Therapy

Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate

(2009) H. Amital et al.   RHEUMATOLOGY

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

(2008) D E Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases

(2008) I. Cavazzana et al.   AUTOIMMUNITY REVIEWS

Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports

(2008) Primal P. Kaur et al.   CLINICAL RHEUMATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept

(2008) Gérard Thiéfin et al.   JOINT BONE SPINE

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection

(2008) AJ Alcaide et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY